Follow us
Evaluation of hPG80 (Circulating Progastrin) As a Multi-Cancer Early Detection (MCED) Test In a Private Clinic in Norway
June 2025
Journals - Gavin Publishers June 2025
Abstract
Background:
Early cancer detection is crucial for effective treatment. In a private clinic in Norway, we evaluated hPG80 (circulating progastrin), a novel blood-based biomarker, as a potential multi-cancer early detection (MCED) test in individuals over 50 at risk for cancer.
Methods:
Plasma EDTA samples from 24 asymptomatic patients were analyzed using the DxPG80.lab ELISA kit (Biodena Care, France) between January and March 2020. Participants were stratified based on hPG80 levels: low (below Limit of Quantification), intermediate (above LoQ but below Upper Limit of Normal), and high (above ULN).
Results:
Three early-stage cancers (colorectal, prostate, and lung) were detected in individuals with intermediate or high hPG80 levels. All were treated successfully, with no relapses after four years.
One patient with high hPG80 levels was initially diagnosed with a premalignant kidney cyst and later developed two separate lung cancers, which were also successfully treated. Four other patients with elevated hPG80 underwent further screening, but no malignancy was found; they remain cancer-free after followup. Sixteen patients with low hPG80 levels have not developed cancer over four years. The study showed a sensitivity of 100%, specificity of 80%, Negative Predictive Value (NPV) of 100%, and Positive Predictive Value (PPV) of 50%.
Conclusion:
hPG80 may detect cancer earlier than conventional methods, supporting its role as a promising MCED tool. Low levels were associated with no cancer development, suggesting hPG80’s potential use for risk stratification and tailored monitoring in clinical settings.